Insider Sell Stephen Carey Sells 7,500 Shares of ANI Pharmaceuticals Inc
| ANIP Stock | USD 54.16 0.05 0.09% |
Slightly above 67% of ANI Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading ANI Pharmaceuticals stock suggests that many investors are alarmed at this time. ANI Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in ANI Pharmaceuticals. Many technical investors use ANI Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ANI |
On December 17, 2024, Stephen Carey, Senior Vice President Chief Financial Officer of ANI Pharmaceuticals Inc , sold 7,500 shares of the company, accord
Read at gurufocus.com
 |
ANI Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards ANI Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ANI Pharmaceuticals Fundamental Analysis
We analyze ANI Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
ANI Pharmaceuticals is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
ANI Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ANI Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
ANI Pharmaceuticals Related Equities
| PCRX | Pacira BioSciences, | 1.41 | ||||
| RDY | Dr Reddys | 1.16 | ||||
| ALKS | Alkermes Plc | 0.51 | ||||
| IRWD | Ironwood Pharmaceuticals | 0.44 | ||||
| PBH | Prestige Brand | 0.24 | ||||
| PAHC | Phibro Animal | 0.23 | ||||
| COLL | Collegium Pharmaceutical | 0.31 | ||||
| NBIX | Neurocrine Biosciences | 0.34 | ||||
| AMPH | Amphastar | 2.17 | ||||
| INCR | INC Research | 5.03 | ||||
| PROC | Procaps Group | 6.06 |
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.